鼻腔疫苗市场 - 全球产业规模、份额、趋势、机会和预测，按疫苗类型、应用（流感、COVID-19、其他）、地区、竞争细分，2020-2030F

2024 年全球鼻腔疫苗市场价值为 4.252 亿美元，预计在预测期内将实现令人印象深刻的成长，到 2030 年的复合年增长率为 6.05%。全球医疗保健格局不断发展，近年来一个重大发展是鼻腔疫苗的出现。鼻腔疫苗为预防各种传染病提供了一种新颖有效的方法，为传统注射疫苗提供了一种非侵入性替代方案。随着疫苗技术的进步和人们对其益处的认识不断提高，全球鼻腔疫苗市场发展势头强劲。近年来，受多种关键因素推动，全球鼻腔疫苗市场实现了大幅成长。其中包括对无痛、便捷的疫苗接种方法的需求不断增长、对预防性医疗保健的日益关注以及创新鼻腔疫苗製剂的开发。鼻腔疫苗对于儿童和害怕针头的人来说特别有吸引力，使其成为免疫接种的首选。市面上经鼻给药的疫苗种类不断扩大。最初，鼻喷疫苗主要与流感疫苗有关，但现在涵盖的疾病范围更广，包括新冠肺炎、麻疹、腮腺炎、德国麻疹等。这种多样化极大地促进了市场的发展。製药公司和研究机构正积极投入研发，以开发更有效、更强效的鼻腔疫苗製剂。这包括增强鼻腔疫苗的稳定性和传递机制。

各国政府和国际组织越来越认识到鼻喷疫苗在提高疫苗接种覆盖率方面的潜力。这导致了对鼻喷疫苗研究和疫苗接种活动的投资增加，特别是在低收入和中等收入国家。公众意识运动和教育工作在提高鼻腔疫苗接受度方面发挥着至关重要的作用。这些活动强调了鼻腔疫苗的优点，例如减轻疼痛、更容易接种和更快地形成免疫力。

肯塔基州市场驱动因素

传染病和呼吸道疾病发生率不断上升

传染病和呼吸道疾病发生率的上升是推动全球鼻腔疫苗市场扩张的主要驱动力。随着全球流感、新冠肺炎、结核病 (TB) 和呼吸道合胞病毒 (RSV) 等疾病负担不断加剧，对有效、可及和非侵入性疫苗接种解决方案的需求日益增加。由于季节性流感和结核病的广泛流行，全球医疗保健产业面临重大挑战。每年，季节性流感影响全球约 10 亿人，其中 300 万至 500 万人会发展为重症。该疾病每年导致约 29 万至 65 万人死于呼吸系统疾病，对医疗保健系统和经济生产力造成巨大压力。

同样，结核病（TB）仍然是全球面临的重大健康挑战。光是 2023 年，全球就有约 1,080 万人感染结核病，其中影响 600 万名男性、360 万名女性和 130 万名儿童。该疾病持续影响所有国家和年龄群体，加剧了其广泛的公共卫生负担。儘管结核病可以治癒和预防，但由于早期发现、治疗机会和医疗保健基础设施方面的差距，结核病仍然存在。鼻腔疫苗可提供有针对性的免疫反应，特别是针对空气传播的病原体，使其成为传统注射疫苗的极具吸引力的替代品。呼吸系统疾病是全世界发病和死亡的主要原因之一。仅流感每年影响数百万人，导致住院、经济压力和生产力损失。同样，像 COVID-19 这样的新兴传染病也强化了对可扩展且易于部署的疫苗接种策略的需求。 2020 年，慢性阻塞性肺病 (COPD) 影响了全球约 10.6% 的人口，男性和女性共有 4.8 亿例。这种慢性呼吸系统疾病将继续扩大，成为主要的公共卫生问题，预计到 2050 年病例将增加 23.3%。到那时，慢性阻塞性肺病病例总数预计将达到 5.92 亿，占全球高风险人口的 9.5%。鼻腔疫苗在预防呼吸系统疾病方面特别有效，因为它们模仿了空气传播病毒和细菌的自然感染途径。感染率高的国家正在加大对预防免疫策略的投资，加速鼻腔疫苗技术的采用。

主要市场挑战

监管障碍

主要市场趋势

技术进步

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：鼻腔疫苗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依疫苗类型（减毒活疫苗、不活化疫苗、次单位疫苗、重组疫苗及结合疫苗、其他）
  • 依用途分类（流感、新冠肺炎、其他（如霍乱、伤寒等））
  • 按地区
  • 按公司分类（2024）
• 市场地图

第 6 章：北美鼻腔疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第 7 章：欧洲鼻腔疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 8 章：亚太地区鼻腔疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲鼻腔疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲鼻腔疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 13 章：全球鼻腔疫苗市场：SWOT 分析

第 14 章：竞争格局

• Vaxart, Inc.
• FluGen Inc.
• Altimmune, Inc.
• Sinovac Biotech Ltd.
• Sanofi Pasteur SA
• Pfizer Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Ennaid Therapeutics, LLC

第 15 章：策略建议

第16章调查会社について・免责事项

Global Nasal Vaccines Market was valued at USD 425.20 Million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.05% through 2030. The global healthcare landscape is continually evolving, and one significant development in recent years is the emergence of nasal vaccines. Nasal vaccines offer a novel and effective way to protect against various infectious diseases, providing a non-invasive alternative to traditional injection-based vaccines. The global nasal vaccines market has been gaining momentum, with advancements in vaccine technology and increasing awareness of their benefits. The global nasal vaccines market has witnessed substantial growth in recent years, driven by several key factors. These include a rising demand for painless and convenient vaccination methods, increased focus on preventive healthcare, and the development of innovative nasal vaccine formulations. Nasal vaccines are particularly appealing for children and individuals who fear needles, making them a preferred choice for immunization. The market has seen the expansion of the types of vaccines delivered nasally. Initially, nasal vaccines were primarily associated with influenza vaccines, but now they cover a wider range of diseases, including COVID-19, measles, mumps, rubella, and more. This diversification has significantly boosted the market. Pharmaceutical companies and research institutions are actively investing in R&D to develop more effective and potent nasal vaccine formulations. This includes enhancing the stability and delivery mechanisms of nasal vaccines.

Governments and international organizations are increasingly recognizing the potential of nasal vaccines in improving vaccination coverage rates. This has led to greater investments in research and vaccination campaigns using nasal vaccines, particularly in low-income and middle-income countries. Public awareness campaigns and educational efforts are playing a vital role in increasing the acceptance of nasal vaccines. These campaigns highlight the advantages of nasal vaccines, such as reduced pain, easier administration, and quicker immunity development.

Ky Market Drivers

Growing Prevalence of Infectious and Respiratory Diseases

The rising incidence of infectious and respiratory diseases is a key driver fueling the expansion of the global nasal vaccines market. As the global burden of diseases such as influenza, COVID-19, tuberculosis (TB), and respiratory syncytial virus (RSV) continues to escalate, there is an increasing demand for effective, accessible, and non-invasive vaccination solutions. The global healthcare sector faces significant challenges due to the widespread prevalence of seasonal influenza and tuberculosis (TB). Each year, seasonal influenza affects approximately one billion people worldwide, with 3 to 5 million cases progressing to severe illness. The disease is responsible for an estimated 290,000 to 650,000 respiratory-related deaths annually, creating substantial strain on healthcare systems and economic productivity.

Similarly, tuberculosis (TB) remains a critical global health challenge. In 2023 alone, an estimated 10.8 million people contracted TB worldwide, affecting 6.0 million men, 3.6 million women, and 1.3 million children. The disease continues to impact all countries and age groups, reinforcing its widespread public health burden. Despite being both curable and preventable, TB persists due to gaps in early detection, treatment access, and healthcare infrastructure. Nasal vaccines provide a targeted immune response, particularly against airborne pathogens, making them a highly attractive alternative to traditional injectable vaccines. Respiratory diseases are among the leading causes of morbidity and mortality worldwide. Influenza alone affects millions annually, leading to hospitalizations, economic strain, and loss of productivity. Similarly, emerging infectious diseases like COVID-19 have reinforced the need for scalable and easily deployable vaccination strategies. In 2020, chronic obstructive pulmonary disease (COPD) affected an estimated 10.6% of the global population, translating to 480 million cases across both men and women. This chronic respiratory condition continues to expand as a major public health concern, with projections indicating a 23.3% increase in cases by 2050. By that time, the total number of COPD cases is expected to reach 592 million, representing 9.5% of the global at-risk population. Nasal vaccines are particularly effective in preventing respiratory diseases because they mimic the natural infection route of airborne viruses and bacteria. Countries with high infection rates are increasingly investing in preventive immunization strategies, thereby accelerating the adoption of nasal vaccine technologies.

Key Market Challenges

Regulatory Hurdles

One of the primary challenges facing the nasal vaccines market is navigating the complex regulatory landscape. The approval process for nasal vaccines can be more challenging compared to traditional injectable vaccines. Regulators need to ensure the safety and efficacy of these vaccines, which can lead to longer development timelines and higher costs. To address this challenge, collaboration between vaccine developers and regulatory agencies is essential to streamline the approval process and establish clear guidelines for nasal vaccine development.

Key Market Trends

Technological Advancements

The global healthcare landscape is constantly evolving, with technological advancements at the forefront of innovation. One significant development is the growing interest in nasal vaccines, a novel approach to immunization that offers numerous advantages over traditional injection-based vaccines. These advancements have ignited a surge in the Global Nasal Vaccines Market, shaping the future of preventive medicine and public health.

Advancements in vaccine formulation have played a pivotal role in the growth of nasal vaccines. Researchers are developing new formulations that enhance vaccine stability, improve antigen delivery, and minimize side effects, thereby increasing their efficacy and safety. Adjuvants are substances added to vaccines to boost the body's immune response. Recent developments in adjuvant technology have led to the creation of nasal vaccines that can trigger stronger and more durable immune responses, improving their overall effectiveness.

Key Market Players

• Vaxart, Inc.
• FluGen Inc.
• Altimmune, Inc.
• Sinovac Biotech Ltd.
• Sanofi Pasteur SA
• Pfizer Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Ennaid Therapeutics, LLC

Report Scope:

In this report, the Global Nasal Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nasal Vaccines Market, By Vaccine Type:

• Live Attenuated Vaccines
• Inactivated Vaccines
• Subunit
• Recombinant and Conjugate Vaccines
• Others

Nasal Vaccines Market, By Application:

• Influenza
• COVID-19
• Others

Nasal Vaccines Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Nasal Vaccines Market.

Available Customizations:

Global Nasal Vaccines market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Nasal Vaccines Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant and Conjugate Vaccines, Others)
  • 5.2.2. By Application (Influenza, COVID-19, Others (such as Cholera, Typhoid, etc.))
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Nasal Vaccines Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Vaccine Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Nasal Vaccines Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Vaccine Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Nasal Vaccines Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Vaccine Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Nasal Vaccines Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Vaccine Type
      • 6.3.3.2.2. By Application

7. Europe Nasal Vaccines Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Vaccine Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Nasal Vaccines Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Vaccine Type
      • 7.3.1.2.2. By Application
  • 7.3.2. United Kingdom Nasal Vaccines Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Vaccine Type
      • 7.3.2.2.2. By Application
  • 7.3.3. Italy Nasal Vaccines Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Vaccine Type
      • 7.3.3.2.2. By Application
  • 7.3.4. France Nasal Vaccines Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Vaccine Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Nasal Vaccines Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Vaccine Type
      • 7.3.5.2.2. By Application

8. Asia-Pacific Nasal Vaccines Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Vaccine Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Nasal Vaccines Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Vaccine Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Nasal Vaccines Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Vaccine Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Nasal Vaccines Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Vaccine Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Nasal Vaccines Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Vaccine Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Nasal Vaccines Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Vaccine Type
      • 8.3.5.2.2. By Application

9. South America Nasal Vaccines Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Vaccine Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Nasal Vaccines Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Vaccine Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Nasal Vaccines Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Vaccine Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Nasal Vaccines Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Vaccine Type
      • 9.3.3.2.2. By Application

10. Middle East and Africa Nasal Vaccines Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Vaccine Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Nasal Vaccines Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Vaccine Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Nasal Vaccines Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Vaccine Type
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Nasal Vaccines Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Vaccine Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Nasal Vaccines Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Vaxart, Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. FluGen Inc.
• 14.3. Altimmune, Inc.
• 14.4. Sinovac Biotech Ltd.
• 14.5. Sanofi Pasteur SA
• 14.6. Pfizer Inc.
• 14.7. GlaxoSmithKline plc
• 14.8. Johnson & Johnson
• 14.9. Ennaid Therapeutics, LLC

15. Strategic Recommendations

16. About Us & Disclaimer